检验医学
檢驗醫學
검험의학
LABORATORY MEDICINE
2015年
4期
318-320
,共3页
申旺%凌寿坚%叶丽燕%杨文丽%谭晓宇
申旺%凌壽堅%葉麗燕%楊文麗%譚曉宇
신왕%릉수견%협려연%양문려%담효우
D-二聚体%非小细胞肺癌%化疗
D-二聚體%非小細胞肺癌%化療
D-이취체%비소세포폐암%화료
D-dimer%Non-small cell lung cancer%Chemotherapy
目的:探讨血浆D-二聚体在非小细胞肺癌( NSCLC )患者中的临床价值。方法采用免疫比浊法检测47例NSCLC患者及66名健康人的血浆D-二聚体水平,对D-二聚体与NSCLC临床分期、病理分型和淋巴转移之间的关系进行分析;通过比较NSCLC患者化疗前后D-二聚体的水平,探讨其与化疗疗效之间的关系。结果NSCLC患者血浆D-二聚体水平[0.96(0.63~1.35) mg/L]较健康对照组[(0.34(0.17~0.39) mg/L]显著升高(P<0.01);不同临床分期和病理分型患者 D-二聚体水平差异均有统计学意义(P<0.05);也与淋巴转移存在相关性(r=0.609,P<0.05)。化疗后,有效组(完全缓解及部分缓解)的血浆D-二聚体水平较化疗前明显下降(P<0.05);稳定组无明显变化(P>0.05);进展组明显升高(P<0.05)。结论血浆 D-二聚体在NSCLC患者的临床分期、病理分型和淋巴转移中具有一定的临床意义,并可作为评估化疗疗效的有效指标。
目的:探討血漿D-二聚體在非小細胞肺癌( NSCLC )患者中的臨床價值。方法採用免疫比濁法檢測47例NSCLC患者及66名健康人的血漿D-二聚體水平,對D-二聚體與NSCLC臨床分期、病理分型和淋巴轉移之間的關繫進行分析;通過比較NSCLC患者化療前後D-二聚體的水平,探討其與化療療效之間的關繫。結果NSCLC患者血漿D-二聚體水平[0.96(0.63~1.35) mg/L]較健康對照組[(0.34(0.17~0.39) mg/L]顯著升高(P<0.01);不同臨床分期和病理分型患者 D-二聚體水平差異均有統計學意義(P<0.05);也與淋巴轉移存在相關性(r=0.609,P<0.05)。化療後,有效組(完全緩解及部分緩解)的血漿D-二聚體水平較化療前明顯下降(P<0.05);穩定組無明顯變化(P>0.05);進展組明顯升高(P<0.05)。結論血漿 D-二聚體在NSCLC患者的臨床分期、病理分型和淋巴轉移中具有一定的臨床意義,併可作為評估化療療效的有效指標。
목적:탐토혈장D-이취체재비소세포폐암( NSCLC )환자중적림상개치。방법채용면역비탁법검측47례NSCLC환자급66명건강인적혈장D-이취체수평,대D-이취체여NSCLC림상분기、병리분형화림파전이지간적관계진행분석;통과비교NSCLC환자화료전후D-이취체적수평,탐토기여화료료효지간적관계。결과NSCLC환자혈장D-이취체수평[0.96(0.63~1.35) mg/L]교건강대조조[(0.34(0.17~0.39) mg/L]현저승고(P<0.01);불동림상분기화병리분형환자 D-이취체수평차이균유통계학의의(P<0.05);야여림파전이존재상관성(r=0.609,P<0.05)。화료후,유효조(완전완해급부분완해)적혈장D-이취체수평교화료전명현하강(P<0.05);은정조무명현변화(P>0.05);진전조명현승고(P<0.05)。결론혈장 D-이취체재NSCLC환자적림상분기、병리분형화림파전이중구유일정적림상의의,병가작위평고화료료효적유효지표。
Objective To investigate the clinical value of the plasma D-dimer detection in patients with non-small cell lung cancer ( NSCLC) .Methods The plasma D-dimer levels of 47 NSCLC patients and 66 healthy subjects were detected by immuno-nephelometry .The relationships between plasma D-dimer level and the clinical stage , pathological type and lymph node metastasis of NSCLC patients were analyzed .The D-dimer levels of NSCLC patients before and after chemotherapy were compared .The relationship between the D-dimer and the efficacy of chemotherapy was analyzed . Results The levels of plasma D-dimer were significantly higher in NSCLC patients [0.96(0.63~1.35) mg/L] than in the healthy subjects [0.34(0.17 ~0.39) mg/L,P<0.01].The levels of plasma D-dimer in different clinical stage groups and pathological type groups were statistically significant ( P<0.05 );and it had relationship with lymph node metastasis (r=0.609, P<0.05).After chemotherapy, the levels of D-dimer in effective groups ( contain complete response group and partial response group ) were significantly decreased (P<0.05).There were no significant changes in stability group (P>0.05) and significant higher in progress group (P<0.05).Conclusions The plasma D-dimer has clinical significance in the clinical stage , pathological type and lymph node metastasis in NSCLC patients , and can be used as an effective indicator to evaluate the efficacy of chemotherapy .